Nasal NK- and T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma and Hodgkin's disease.
about
Epstein-Barr virus BamHi-a rightward transcript-encoded RPMS protein interacts with the CBF1-associated corepressor CIR to negatively regulate the activity of EBNA2 and NotchICMolecular diagnosis of Epstein-Barr virus-related diseasesAdoptive T-Cell ImmunotherapyPeripheral T-cell and NK-cell lymphomas in the WHO classification: pearls and pitfallsTherapeutic implications of Epstein-Barr virus infection for the treatment of nasopharyngeal carcinomaAggressive mature natural killer cell neoplasms: from epidemiology to diagnosisQuiescent nasal T/NK cell lymphoma manifested as primary central nervous system lymphoma.IL-21 imposes a type II EBV gene expression on type III and type I B cells by the repression of C- and activation of LMP-1-promoter.Ascorbic acid kills Epstein-Barr virus positive Burkitt lymphoma cells and Epstein-Barr virus transformed B-cells in vitro, but not in vivo.The Epstein-Barr virus major latent promoter Qp is constitutively active, hypomethylated, and methylation sensitiveEBV latency types adopt alternative chromatin conformations.Treatment strategies for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH).Epstein-Barr virus BART9 miRNA modulates LMP1 levels and affects growth rate of nasal NK T cell lymphomasHLA-A*02:07 is a protective allele for EBV negative and a susceptibility allele for EBV positive classical Hodgkin lymphoma in ChinaA novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy.miRNAs in the pathogenesis of oncogenic human viruses.Epstein-Barr virus infection in humans: from harmless to life endangering virus-lymphocyte interactions.A20 (TNFAIP3) deletion in Epstein-Barr virus-associated lymphoproliferative disorders/lymphomas.Burkitt's lymphoma: the Rosetta Stone deciphering Epstein-Barr virus biology.Extranodal NK/T-cell lymphoma: toward the identification of clinical molecular targetsDeciphering the role of Epstein-Barr virus in the pathogenesis of T and NK cell lymphoproliferationsTonsillar memory B cells, latently infected with Epstein-Barr virus, express the restricted pattern of latent genes previously found only in Epstein-Barr virus-associated tumors.Prognostic biomarkers in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy.Frequent deletion of Fas gene sequences encoding death and transmembrane domains in nasal natural killer/T-cell lymphoma.Epstein-Barr virus LMP1 modulates the malignant potential of gastric carcinoma cells involving apoptosis.Methylation status of the Epstein-Barr virus major latent promoter C in iatrogenic B cell lymphoproliferative disease. Application of PCR-based analysis.Consistent patterns of allelic loss in natural killer cell lymphoma.Sequence analysis of Epstein-Barr virus (EBV) early genes BARF1 and BHRF1 in NK/T cell lymphoma from Northern China.Nasal NK/T-cell lymphoma: epidemiology and pathogenesisEpstein-barr virus and the pathogenesis of T and NK lymphoma: a mystery unsolved.Modes of infection and oncogenesis by the Epstein-Barr virus.Nasal and nasal type CD56+ natural killer cell/T-cell lymphoma: a case with rapid progression to bone marrow involvement.EBV Persistence--Introducing the Virus.Clonal deleted latent membrane protein 1 variants of Epstein-Barr virus are predominant in European extranodal NK/T lymphomas and disappear during successful treatment.Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir.Epstein-Barr virus: more than 50 years old and still providing surprises.Emerging insights on the pathogenesis and treatment of extranodal NK/T cell lymphomas (ENKTL).EBV lytic infection enhances transformation of B-lymphocytes infected with EBV in the presence of T-lymphocytes.Evidence for early infection of nonneoplastic natural killer cells by Epstein-Barr virus.Molecular analysis of tumor suppressor genes, Rb, p53, p16INK4A, p15INK4B and p14ARF in natural killer cell neoplasms.
P2860
Q24530175-7118F454-D138-42B4-A9F1-FDCCA8B70CC0Q24680502-7CF9C17F-75ED-4296-8D6D-627C7985A109Q26782845-F8E35477-F3FA-48F8-B490-06C12E226E77Q27004241-A04E6333-CA2C-4D96-B6A1-80EFB208383EQ27016002-7EA023D1-8A13-4094-9318-386A294A8B1BQ27022519-B5EEFFD0-3CDF-4859-9FC3-D9D5B30AC722Q31917410-AA214DF1-63F8-4DAF-8540-1688506034E9Q33640213-09E76AE0-5F0B-44F0-8DF8-27421043405EQ33748089-E9780D87-E66E-4036-8EF6-2F4113591DADQ33783746-D29968C0-B5D8-4AD7-A9B2-88786AD2F328Q33987454-4FFA1F39-6A32-4393-B7C4-E8E71A531F25Q34024242-28C32605-3EB7-40A3-9C99-909A18932372Q34079271-D0879902-EE10-4AFF-875F-A29382346CCDQ34166497-D06279C2-D885-45A6-BDE7-290CE3E7506DQ34310840-D892C14F-A37D-4A53-A0F9-48FE673BCEBAQ34504522-BAC53041-CAF3-421A-93D9-9FC96AB33AD9Q34576340-DB0A4466-2E03-42B4-BBB7-459B6116C526Q34590254-478D1004-13FE-4017-9747-C564A63D0B1EQ34658852-E691C2AD-26AB-475B-BED5-1262DE9C111BQ34898306-6B3F7027-50E6-4BDF-A4F6-8C837997C2ADQ35232848-1DF00630-335B-4F25-B9B1-09CEA51F7252Q35414637-CE5049D5-DF8C-4CFA-ABEC-6F1D83E2B76AQ35713503-F3287AE9-E662-404B-B0B1-64551909FB9AQ35748214-27CC86C6-3AF5-4CD2-B0EB-49A1C6A60943Q35764233-14138C94-D337-473E-B2F3-22B2991B8012Q35787708-41A1522F-EBD9-4CF0-87B9-CF79E431566BQ35829661-8B7ED4E6-2014-4FC3-BE0D-FB1810DD07FCQ36023207-D27D3D77-69BA-4AC6-8EC4-C6AE424C5B2EQ36511890-D14E0394-9673-4A83-A978-4C779153FEDBQ38043974-2BB45ECF-BB3C-47E1-B483-87BD86326793Q38191876-E07F8240-356D-4B56-B362-DB3E8F973046Q38526381-15BD9E50-7589-47FF-A707-2CA38452F095Q38596344-C92A8E51-7E22-4E6F-8ABD-3C9592FA8C40Q38779524-56809343-5C4C-4008-95D3-5CA9FDCB815DQ38849926-1BEE7869-3380-4E84-BE84-B72EEC75C670Q38968588-6DCC6712-B61D-4F52-BF50-B1F7A5647D4EQ39284101-F572FDC7-D4F7-42A1-A51E-1CB68035FF5AQ39411850-2D949C63-EB75-4D71-9B76-3CFD9526D2BBQ39685222-EED2D01C-07A7-4AEF-8468-E71579D0EB45Q40772738-2F5FBDA9-4166-436D-AD72-9D51F3E8A999
P2860
Nasal NK- and T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma and Hodgkin's disease.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
Nasal NK- and T-cell lymphomas ...... rcinoma and Hodgkin's disease.
@en
Nasal NK- and T-cell lymphomas ...... rcinoma and Hodgkin's disease.
@nl
type
label
Nasal NK- and T-cell lymphomas ...... rcinoma and Hodgkin's disease.
@en
Nasal NK- and T-cell lymphomas ...... rcinoma and Hodgkin's disease.
@nl
prefLabel
Nasal NK- and T-cell lymphomas ...... rcinoma and Hodgkin's disease.
@en
Nasal NK- and T-cell lymphomas ...... rcinoma and Hodgkin's disease.
@nl
P2093
P2860
P1476
Nasal NK- and T-cell lymphomas ...... rcinoma and Hodgkin's disease.
@en
P2093
P2860
P304
P356
10.1002/(SICI)1097-0215(19961104)68:3<285::AID-IJC3>3.0.CO;2-Y
P577
1996-11-01T00:00:00Z